Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linavonkibart alone and in combination with anti-PD-(L)1 in advanced solid tumors
NCT04291079Phase 1Completed
- Sponsor
- Scholar Rock
- Start
- Apr 2020
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label trial of srk-181 in solid tumor, non-small cell lung cancer (NSCLC), urothelial carcinoma (UC) and 3 more (4 arms), sponsored by Scholar Rock. Primary endpoints: Safety and tolerability of single agent SRK-181 at 21 days and Safety and tolerability of SRK-181 in combination with anti-PD-(L)1 antibody therapy at 21 days. Started Apr 2020; status: completed.
02
Drugs
srk-181
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)urothelial carcinoma (UC)melanomaclear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04291079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04291079.